PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Grandl, G. ; Novikoff, A. ; Liu, X. ; Müller, T.D.

Recent achievements and future directions of anti-obesity medications.

Lancet Reg. Health-Eur. 47:101100 (2024)
Verlagsversion DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
Pharmacological management of obesity long suffered from a reputation of a 'Mission Impossible,' with inefficient weight loss and/or unacceptable tolerability. However, the tide has turned with recent progress in biochemical engineering and the development of long-acting agonists at the receptor for glucagon-like peptide-1 (GLP-1), and with unimolecular peptides that simultaneously possess activity at the receptors for GLP-1, the glucose-dependent insulinotropic polypeptide (GIP) and glucagon. Some of these novel therapeutics not only improve body weight and glycemic control in individuals with obesity and type 2 diabetes with hitherto unmet efficacy and tolerable safety, but also exhibit potential therapeutic value in diverse areas such as neurodegenerative diseases, fatty liver disease, dyslipidemia, atherosclerosis, and cardiovascular diseases. In this review, we highlight recent advances in incretin-based therapies and discuss their pharmacological potential within and beyond the treatment of obesity and diabetes, as well as their limitations in use, side effects, and underlying molecular mechanisms.
Impact Factor
Scopus SNIP
Altmetric
13.600
0.000
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Review
Schlagwörter Anti-obesity Medication (aom) ; Diabetes ; Gip ; Glp-1 ; Obesity; Glucagon-like Peptide-1; Dependent Insulinotropic Polypeptide; Once-weekly Semaglutide; Glp-1 Receptor Agonist; Inhibits Bone-resorption; Double-blind; Cardiovascular Outcomes; Parallel-group; Body-weight; Open-label
Sprache englisch
Veröffentlichungsjahr 2024
HGF-Berichtsjahr 2024
ISSN (print) / ISBN 2666-7762
e-ISSN 2666-7762
Zeitschrift The Lancet Regional Health - Europe
Quellenangaben Band: 47, Heft: , Seiten: , Artikelnummer: 101100 Supplement: ,
Verlag Elsevier
Verlagsort Radarweg 29, 1043 Nx Amsterdam, Netherlands
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Diabetes and Obesity (IDO)
POF Topic(s) 90000 - German Center for Diabetes Research
30201 - Metabolic Health
Forschungsfeld(er) Helmholtz Diabetes Center
PSP-Element(e) G-501900-221
G-502200-001
G-502296-001
Förderungen German Center for Diabetes Research (DZD e.V.)
German Research Foundation
Neither the European Union
European Union
DOI 10.1016/j.lanepe.2024.101100
WOS ID 001371113600001
PubMed ID 39582489
Erfassungsdatum 2024-12-03
[➜Korrektur melden]